Medco-FDA PGx Alliance Aims to Improve Rx Efficacy, Safety, Consider Label Updates
August 20, 2008
Medco-FDA PGx Alliance Aims to Improve Rx Efficacy, Safety, Consider Label Updates
The FDA plans to use Medco’s large claims database to understand “the real-world application of a test,” inform pharmacogenomics assessments of drug safety and efficacy, and update drug labels with genetic risk information.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Q&A: INMEGEN's Alfredo Hidalgo on Using Genomics to Address Mexico's Most Pressing Health Problems
May 17, 2013 / BioArray News - European Consortium Investigating Molecular Basis of IBD
May 17, 2013 / GenomeWeb Daily News - GMU Team Builds Phosphoproteomic-based Pathway Activation Profiles of NCI-60 Cancer Cell Lines
May 17, 2013 / ProteoMonitor - Vermillion Posts 8 Percent Increase in OVA1 Sales, Announces Shift in Commercialization Strategy
May 17, 2013 / ProteoMonitor - NIDDK to Fund Biomarker, Assay Projects Using Samples and Data from Its Repository
May 17, 2013 / GenomeWeb Daily News